Stay updated on IDA53 Clinical Trial

Sign up to get notified when there's something new on the IDA53 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IDA53 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study details regarding the evaluation of the safety and efficacy of combining daratumumab and ibrutinib in relapsed/refractory chronic lymphocytic leukemia patients with TP53 dysfunction.
    Difference
    0.1%
    Check dated 2024-06-06T14:36:36.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    19%
    Check dated 2024-05-22T21:23:42.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:56:23.000Z thumbnail image

Stay in the know with updates to IDA53 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IDA53 Clinical Trial page.